Cargando…
Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system
The irradiation field of boron neutron capture therapy (BNCT) consists of multiple dose components including thermal, epithermal and fast neutron, and gamma. The objective of this work was to establish a methodology of dosimetric quality assurance (QA), using the most standard and reliable measureme...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303606/ https://www.ncbi.nlm.nih.gov/pubmed/35726375 http://dx.doi.org/10.1093/jrr/rrac030 |
_version_ | 1784751908098932736 |
---|---|
author | Hirose, Katsumi Kato, Takahiro Harada, Takaomi Motoyanagi, Tomoaki Tanaka, Hiroki Takeuchi, Akihiko Kato, Ryohei Komori, Shinya Yamazaki, Yuhei Arai, Kazuhiro Kadoya, Noriyuki Sato, Mariko Takai, Yoshihiro |
author_facet | Hirose, Katsumi Kato, Takahiro Harada, Takaomi Motoyanagi, Tomoaki Tanaka, Hiroki Takeuchi, Akihiko Kato, Ryohei Komori, Shinya Yamazaki, Yuhei Arai, Kazuhiro Kadoya, Noriyuki Sato, Mariko Takai, Yoshihiro |
author_sort | Hirose, Katsumi |
collection | PubMed |
description | The irradiation field of boron neutron capture therapy (BNCT) consists of multiple dose components including thermal, epithermal and fast neutron, and gamma. The objective of this work was to establish a methodology of dosimetric quality assurance (QA), using the most standard and reliable measurement methods, and to determine tolerance level for each QA measurement for a commercially available accelerator-based BNCT system. In order to establish a system of dosimetric QA suitable for BNCT, the following steps were taken. First, standard measurement points based on tissue-administered doses in BNCT for brain tumors were defined, and clinical tolerances of dosimetric QA measurements were derived from the contribution to total tissue relative biological effectiveness factor-weighted dose for each dose component. Next, a QA program was proposed based on TG-142 and TG-198, and confirmed that it could be assessed whether constancy of each dose component was assured within the limits of tolerances or not by measurements of the proposed QA program. Finally, the validity of the BNCT QA program as an evaluation system was confirmed in a demonstration experiment for long-term measurement over 1 year. These results offer an easy, reliable QA method that is clinically applicable with dosimetric validity for the mixed irradiation field of accelerator-based BNCT. |
format | Online Article Text |
id | pubmed-9303606 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-93036062022-07-22 Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system Hirose, Katsumi Kato, Takahiro Harada, Takaomi Motoyanagi, Tomoaki Tanaka, Hiroki Takeuchi, Akihiko Kato, Ryohei Komori, Shinya Yamazaki, Yuhei Arai, Kazuhiro Kadoya, Noriyuki Sato, Mariko Takai, Yoshihiro J Radiat Res Fundamental Radiation Science The irradiation field of boron neutron capture therapy (BNCT) consists of multiple dose components including thermal, epithermal and fast neutron, and gamma. The objective of this work was to establish a methodology of dosimetric quality assurance (QA), using the most standard and reliable measurement methods, and to determine tolerance level for each QA measurement for a commercially available accelerator-based BNCT system. In order to establish a system of dosimetric QA suitable for BNCT, the following steps were taken. First, standard measurement points based on tissue-administered doses in BNCT for brain tumors were defined, and clinical tolerances of dosimetric QA measurements were derived from the contribution to total tissue relative biological effectiveness factor-weighted dose for each dose component. Next, a QA program was proposed based on TG-142 and TG-198, and confirmed that it could be assessed whether constancy of each dose component was assured within the limits of tolerances or not by measurements of the proposed QA program. Finally, the validity of the BNCT QA program as an evaluation system was confirmed in a demonstration experiment for long-term measurement over 1 year. These results offer an easy, reliable QA method that is clinically applicable with dosimetric validity for the mixed irradiation field of accelerator-based BNCT. Oxford University Press 2022-06-20 /pmc/articles/PMC9303606/ /pubmed/35726375 http://dx.doi.org/10.1093/jrr/rrac030 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Fundamental Radiation Science Hirose, Katsumi Kato, Takahiro Harada, Takaomi Motoyanagi, Tomoaki Tanaka, Hiroki Takeuchi, Akihiko Kato, Ryohei Komori, Shinya Yamazaki, Yuhei Arai, Kazuhiro Kadoya, Noriyuki Sato, Mariko Takai, Yoshihiro Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system |
title | Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system |
title_full | Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system |
title_fullStr | Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system |
title_full_unstemmed | Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system |
title_short | Determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system |
title_sort | determining a methodology of dosimetric quality assurance for commercially available accelerator-based boron neutron capture therapy system |
topic | Fundamental Radiation Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303606/ https://www.ncbi.nlm.nih.gov/pubmed/35726375 http://dx.doi.org/10.1093/jrr/rrac030 |
work_keys_str_mv | AT hirosekatsumi determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem AT katotakahiro determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem AT haradatakaomi determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem AT motoyanagitomoaki determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem AT tanakahiroki determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem AT takeuchiakihiko determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem AT katoryohei determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem AT komorishinya determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem AT yamazakiyuhei determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem AT araikazuhiro determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem AT kadoyanoriyuki determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem AT satomariko determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem AT takaiyoshihiro determiningamethodologyofdosimetricqualityassuranceforcommerciallyavailableacceleratorbasedboronneutroncapturetherapysystem |